354 related articles for article (PubMed ID: 34035112)
1. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
2. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
3. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
4. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM
J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
8. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
[TBL] [Abstract][Full Text] [Related]
9. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA
Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780
[TBL] [Abstract][Full Text] [Related]
10. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
[TBL] [Abstract][Full Text] [Related]
11. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
[TBL] [Abstract][Full Text] [Related]
12. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
Patel SP; Petroni GR; Roszik J; Olson WC; Wages NA; Chianese-Bullock KA; Smolkin M; Varhegyi N; Gaughan E; Smith KT; Haden K; Hall EH; Gnjatic S; Hwu P; Slingluff CL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413169
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
16. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.
Salerno EP; Shea SM; Olson WC; Petroni GR; Smolkin ME; McSkimming C; Chianese-Bullock KA; Slingluff CL
Cancer Immunol Immunother; 2013 Jul; 62(7):1149-59. PubMed ID: 23657629
[TBL] [Abstract][Full Text] [Related]
17. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
18. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
[No Abstract] [Full Text] [Related]
19. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
20. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
